DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

Information source: University of Malaya
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Airway Response

Intervention: alfentanil (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: University of Malaya

Official(s) and/or principal investigator(s):
Lee Chew Kiok, MBBS, Principal Investigator, Affiliation: Department of Anaesthesiogy, UMMC.

Overall contact:
Lee Chew Kiok, MBBS, Phone: 0162737229, Email: cklee1127@yahoo.com

Summary

This study aims to determine the optimal dose of alfentanil in suppressing the airway reflexes during supreme LMA removal in anaesthetized adult.

Clinical Details

Official title: Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)

Primary outcome: Optimal dose of alfentanil for successful LMA removal in spontaneously breathing anaesthetized adults

Secondary outcome: Nunber of patient with airway complication

Detailed description: The removal of LMA may be associated with coughing, biting, agitation and airway complication such as laryngospasm. Thus it is advisable to remove the LMA when the patient is breathing spontaneously and when the airway reflexes are still depressed. A number of techniques have been used to prevent this adverse emergence phenomenon, such as removing the tube while the patient is in deep plane of anaesthesia or administration of local anaesthetic and intravenous opioids The administration of intravenous opioids before emergence may be useful for preventing cough, agitation and hemodynamic response. Alfentanyl is proven to suppress cough and agitation during the endotracheal tube emergence. However, its use in suppressing cough in LMA patient has not been evaluated.

Eligibility

Minimum age: 18 Years. Maximum age: 49 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. ASA I and II patients 2. Age 18 to 49 years old 3. Minor elective day care surgery (> 20 minute and less than 2 hours) which require local anaesthetic infiltration and does not require use of long acting opioids. Exclusion Criteria: 1. Potential difficult airway 2. Reactive airway disease or sign and symptoms of upper respiratory tract infection. 3. History of cardiac, pulmonary and renal diseases 4. Body Mass Index > 30 kgm2. 5. Risk of aspiration. 6. Poor dentition with high risk of damage. 7. Patient refusal.

Locations and Contacts

Lee Chew Kiok, MBBS, Phone: 0162737229, Email: cklee1127@yahoo.com

University Malaya Medical Centre, Lembah Pantai, Kuala Lumpur 59100, Malaysia; Recruiting
Lee Chew Kiok, MBBS, Phone: 0162737229, Email: cklee1127@yahoo.com
Wang Chew Yin, Phone: 0192340232, Email: wangcy1836@gmail.com
Lee Chew Kiok, MBBS, Principal Investigator
Additional Information

Starting date: February 2011
Last updated: June 10, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017